Equities research analysts expect 2seventy bio, Inc. (NASDAQ:TSVT – Get Rating) to post earnings of ($1.17) per share for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for 2seventy bio’s earnings, with the lowest EPS estimate coming in at ($1.78) and the highest estimate coming in at ($0.80). The business is expected to issue its next earnings results on Monday, January 1st.
On average, analysts expect that 2seventy bio will report full year earnings of ($5.40) per share for the current fiscal year, with EPS estimates ranging from ($7.01) to ($2.37). For the next financial year, analysts forecast that the business will post earnings of ($4.58) per share, with EPS estimates ranging from ($6.79) to ($1.94). Zacks’ EPS averages are an average based on a survey of research analysts that follow 2seventy bio.
2seventy bio (NASDAQ:TSVT – Get Rating) last released its earnings results on Thursday, May 12th. The company reported ($3.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.26) by ($0.94). The company had revenue of $8.43 million during the quarter, compared to analysts’ expectations of $22.66 million. 2seventy bio’s revenue for the quarter was down 29.2% compared to the same quarter last year. During the same quarter last year, the firm posted ($3.73) earnings per share.
Shares of TSVT stock traded up $0.22 during trading hours on Monday, hitting $12.14. 5,937 shares of the company’s stock were exchanged, compared to its average volume of 446,443. 2seventy bio has a fifty-two week low of $10.57 and a fifty-two week high of $64.00. The business’s 50 day moving average price is $15.19.
A number of hedge funds have recently added to or reduced their stakes in TSVT. Metropolitan Life Insurance Co NY acquired a new position in 2seventy bio during the 1st quarter valued at about $25,000. Ameritas Investment Partners Inc. acquired a new position in shares of 2seventy bio in the first quarter worth $30,000. Group One Trading L.P. purchased a new stake in shares of 2seventy bio during the 1st quarter worth about $69,000. GSA Capital Partners LLP bought a new stake in 2seventy bio in the first quarter worth $183,000. Finally, Fiduciary Trust Co. bought a new position in shares of 2seventy bio in the 1st quarter valued at approximately $188,000. Hedge funds and other institutional investors own 50.43% of the company’s stock.
2seventy bio Company Profile (Get Rating)
2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma.
- Get a free copy of the StockNews.com research report on 2seventy bio (TSVT)
- Warby Parker Stock Is A High-Probability Candidate For A Short-Squeeze
- Concentrix: High Debt and Struggling Margins
- Recession Fears Mount After Weak Manufacturing Data
- WD-40 Stock is Ready to Coil like a Piston
- CarMax Stock is Poised to Bounce
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for 2seventy bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 2seventy bio and related companies with MarketBeat.com's FREE daily email newsletter.